TNDM - Tandem Diabetes Care Inc Stock Price, Fair Value and News

31.76USD-1.20 (-3.64%)Market Closed

Market Summary

USD31.76-1.20

Market Closed

-3.64%

TNDM Stock Price

View Fullscreen

TNDM RSI Chart

TNDM Valuation

Market Cap

2.2B

Price/Earnings (Trailing)

-9.73

Price/Sales (Trailing)

2.9

EV/EBITDA

-12.02

Price/Free Cashflow

-36.94

TNDM Price/Sales (Trailing)

TNDM Profitability

EBT Margin

-29.46%

Return on Equity

-70.98%

Return on Assets

-23.37%

Free Cashflow Yield

-2.71%

TNDM Fundamentals

TNDM Revenue

Revenue (TTM)

747.7M

Rev. Growth (Yr)

-10.75%

Rev. Growth (Qtr)

6.02%

TNDM Earnings

Earnings (TTM)

-222.6M

Earnings Growth (Yr)

-89.26%

Earnings Growth (Qtr)

8.98%

Breaking Down TNDM Revenue

Last 7 days

-5.4%

Last 30 days

15.3%

Last 90 days

36.8%

Trailing 12 Months

-21%

How does TNDM drawdown profile look like?

TNDM Financial Health

Current Ratio

3.83

Debt/Equity

0.91

Debt/Cashflow

-0.11

TNDM Investor Care

Shares Dilution (1Y)

1.71%

Diluted EPS (TTM)

-3.44

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	794.7M	790.3M	771.4M	747.7M
2022	737.7M	765.8M	790.7M	801.2M
2021	541.9M	604.8M	660.9M	702.8M
2020	394.2M	410.2M	439.2M	498.8M
2019	222.6M	281.7M	330.1M	362.3M
2018	115.9M	128.7M	148.0M	183.9M
2017	83.2M	81.5M	96.2M	107.6M
2016	80.6M	87.9M	84.5M	84.2M
2015	54.0M	59.4M	61.6M	72.8M
2014	31.6M	36.3M	42.1M	49.7M
2013	9.1M	15.7M	22.4M	29.0M
2012	0	0	0	2.5M

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224

Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Tandem Diabetes Care Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 15, 2024	carpenter rick	sold (taxes)	-4,149	28.62	-145	chief technology officer
Mar 15, 2024	carpenter rick	acquired	-	-	405	chief technology officer
Feb 27, 2024	gasser elizabeth anne	sold (taxes)	-3,554	27.34	-130	evp, chief strategy officer
Feb 27, 2024	morrison susan	sold (taxes)	-3,089	27.34	-113	evp & chief admin. officer
Feb 27, 2024	leal james	acquired	-	-	309	chief manufacturing officer
Feb 27, 2024	leal james	sold (taxes)	-3,417	27.34	-125	chief manufacturing officer
Feb 27, 2024	morrison susan	acquired	-	-	407	evp & chief admin. officer
Feb 27, 2024	gasser elizabeth anne	acquired	-	-	372	evp, chief strategy officer
Feb 27, 2024	vosseller leigh	sold (taxes)	-3,882	27.34	-142	evp & chief financial officer
Feb 27, 2024	sheridan john f	acquired	-	-	819	president & ceo

Which funds bought or sold TNDM recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 16, 2024	180 WEALTH ADVISORS, LLC	reduced	-4.77	43,340	271,028	0.05%
Apr 16, 2024	MCF Advisors LLC	added	79.32	19,028	35,623	-%
Apr 16, 2024	TOTH FINANCIAL ADVISORY CORP	unchanged	-	1,895	11,509	-%
Apr 15, 2024	Legato Capital Management LLC	added	66.74	318,505	638,265	0.08%
Apr 15, 2024	Chicago Capital, LLC	added	40.75	9,663,110	23,770,900	0.72%
Apr 15, 2024	Security National Bank	sold off	-100	-769	-	-%
Apr 12, 2024	Westend Capital Management, LLC	new	-	956	956	-%
Apr 12, 2024	AdvisorNet Financial, Inc	unchanged	-	8,745	53,115	-%
Apr 11, 2024	SALEM INVESTMENT COUNSELORS INC	unchanged	-	5,830	35,410	-%
Apr 10, 2024	Banque Cantonale Vaudoise	reduced	-12.43	1,000	11,000	-%

Are Funds Buying or Selling TNDM?

Are funds buying TNDM calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own TNDM

No. of Funds

Unveiling Tandem Diabetes Care Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	eminence capital, lp	7.9%	5,170,451	SC 13G
Feb 13, 2024	vanguard group inc	10.77%	7,021,906	SC 13G/A
Feb 09, 2024	fmr llc	-	0	SC 13G/A
Feb 09, 2024	capital world investors	10.0%	6,536,778	SC 13G/A
Jan 23, 2024	blackrock inc.	14.2%	9,259,187	SC 13G/A
Jun 12, 2023	fmr llc	-	0	SC 13G/A
May 10, 2023	capital world investors	10.0%	6,473,192	SC 13G/A
Apr 10, 2023	vanguard group inc	10.92%	7,047,477	SC 13G/A
Apr 06, 2023	blackrock inc.	14.3%	9,206,880	SC 13G/A
Feb 13, 2023	capital world investors	7.7%	4,978,524	SC 13G/A

Recent SEC filings of Tandem Diabetes Care Inc

View All Filings

Date Filed	Form Type	Document
Apr 09, 2024	ARS	ARS
Apr 09, 2024	DEF 14A	DEF 14A
Apr 09, 2024	DEFA14A	DEFA14A
Apr 01, 2024	8-K	Current Report
Mar 19, 2024	4	Insider Trading
Mar 11, 2024	8-K	Current Report
Feb 29, 2024	4	Insider Trading
Feb 29, 2024	4	Insider Trading
Feb 29, 2024	4	Insider Trading
Feb 29, 2024	4	Insider Trading

Peers (Alternatives to Tandem Diabetes Care Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
ABT	183.7B	40.1B	-5.40%	4.53%	32.1	4.58	-8.12%	-17.45%
BDX	67.1B	19.5B	-2.42%	-9.87%	53.41	3.44	4.02%	-22.04%
ALGN	22.6B	3.9B	-2.94%	-12.25%	50.69	5.84	3.42%	23.09%
BAX	20.1B	14.8B	-4.93%	-7.94%	7.56	1.35	2.12%	209.17%
MID-CAP
ATR	9.2B	3.5B	-1.69%	15.70%	32.17	2.62	4.97%	18.89%
HSIC	9.0B	12.3B	-4.49%	-14.03%	21.69	0.73	-2.44%	-22.68%
BIO	8.5B	2.7B	-12.27%	-39.23%	-13.34	3.18	-4.68%	82.43%
XRAY	6.3B	4.0B	-6.21%	-24.72%	-46.81	1.59	1.10%	85.84%
AXNX	3.4B	366.4M	-0.75%	15.36%	-564.66	9.35	33.86%	89.83%
PDCO	2.3B	6.6B	-5.91%	-4.69%	11.86	0.35	2.78%	-0.87%
SMALL-CAP
AHCO	1.3B	3.2B	-6.61%	-18.37%	-1.85	0.39	7.73%	-1066.14%
ANIK	382.1M	166.7M	0.59%	-11.05%	-4.62	2.29	6.67%	-456.34%
ANGO	253.5M	324.0M	21.04%	-28.41%	-1.32	0.78	-3.19%	-337.41%
APYX	48.2M	52.3M	-22.35%	-53.67%	-2.57	0.92	17.61%	19.28%
AEMD	3.8M	3.7M	-16.76%	269.23%	-0.31	1.01	5.77%	8.23%

Tandem Diabetes Care Inc News

Latest updates

Tandem Diabetes Care Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	6.0%	196,796	185,622	195,917	169,383	220,502	204,547	200,262	175,907	209,996	179,627	172,139	141,037	168,065	123,603	109,236	97,926	108,398	94,657	93,255	65,995	76,199
Gross Profit	3.9%	93,295	89,753	101,735	82,907	115,523	104,425	101,946	91,093	113,729	96,745	92,454	73,287	90,556	65,313	54,390	50,261	60,272	50,683	49,904	33,353	41,535
Operating Expenses	5.8%	128,355	121,298	140,543	210,724	133,300	151,918	114,185	106,431	100,991	89,025	87,022	76,524	71,894	66,322	66,427	63,834	58,128	56,687	51,769	44,350	40,975
S&GA Expenses	8.1%	85,751	79,328	97,610	89,814	97,692	84,104	80,614	73,271	71,499	64,923	66,523	58,563	54,518	50,228	50,440	49,717	45,561	44,649	40,565	34,961	32,178
R&D Expenses	-	-	-	-	-	-	-	33,571	33,160	29,492	24,102	20,499	17,961	17,376	16,094	15,987	14,117	12,568	12,038	11,204	9,389	8,797
EBITDA Margin	-Infinity%	-0.27*	-	-0.26*	-0.23*	-0.10*	-0.06*	0.01*	0.03*	0.05*	0.06*	0.04*	-0.02*	-0.05*	-	-	-	-	-	-	-	-
Interest Expenses	-	-	-	-	-	2,157	-	-	-	2,157	-	-	-	-	-	-	-	-	-	-	-	4,964
Income Taxes	-158.9%	-1,314	2,232	1,146	300	-247	1,600	2,100	-1,724	329	54.00	61.00	-100	51.00	39.00	-2,100	98.00	77.00	72.00	-	-	51.00
Earnings Before Taxes	-2.1%	-31,339	-30,700	-34,629	-123,600	-16,157	-47,300	-12,950	-16,439	11,123	5,848	4,069	-5,161	17,069	-9,400	-29,182	-14,800	2,729	-2,829	-1,512	-	-
EBT Margin	-10.8%	-0.29*	-0.27*	-0.28*	-0.25*	-0.12*	-0.08*	-0.02*	0.01*	0.02*	0.03*	0.01*	-0.05*	-	-	-	-	-	-	-	-	-
Net Income	9.0%	-30,002	-32,961	-35,775	-123,873	-15,852	-48,970	-15,056	-14,715	10,808	5,794	4,008	-5,044	17,000	-9,408	-27,107	-14,867	2,652	-2,901	-1,512	-22,992	3,686
Net Income Margin	-10.2%	-0.30*	-0.27*	-0.28*	-0.26*	-0.12*	-0.09*	-0.02*	0.01*	0.02*	0.03*	0.01*	-0.05*	-	-	-	-	-	-	-	-	-
Free Cashflow	-132.3%	-12,415	-5,345	-13,700	-27,154	193	10,233	-5,216	11,157	13,889	31,049	27,080	25,161	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	1.4%	953	940	947	954	1,053	1,048	1,037	1,015	905	850	795	754	716	673	616	343	326	293	255	215	206
Current Assets	-1.3%	748	758	764	758	850	834	835	818	812	755	698	662	637	592	540	281	276	247	213	186	188
Cash Equivalents	-26.1%	59.00	80.00	131	128	173	124	115	94.00	71.00	112	99.00	121	95.00	129	222	74.00	51.00	46.00	38.00	40.00	42.00
Inventory	10.1%	158	143	148	132	111	105	88.00	80.00	69.00	66.00	67.00	67.00	64.00	71.00	62.00	60.00	49.00	41.00	27.00	23.00	20.00
Net PPE	1.0%	77.00	76.00	74.00	75.00	69.00	73.00	59.00	50.00	50.00	50.00	49.00	50.00	50.00	49.00	44.00	38.00	33.00	28.00	23.00	17.00	17.00
Liabilities	2.1%	639	626	617	615	613	626	587	578	472	461	449	441	350	346	349	136	131	126	110	94.00	75.00
Current Liabilities	4.4%	195	187	175	171	165	174	139	132	132	120	109	103	104	106	114	100	99.00	100	84.00	77.00	66.00
Long Term Debt	0.2%	285	285	284	284	283	283	282	282	281	281	281	280	203	199	195	-	-	-	-	-	-
LT Debt, Non Current	0.2%	285	285	284	284	283	283	282	282	281	281	281	280	203	199	195	-	-	-	-	-	-
Shareholder's Equity	-0.1%	314	314	329	339	440	422	450	437	433	390	346	313	366	327	268	207	195	167	145	121	131
Retained Earnings	-3.3%	-951	-921	-888	-853	-729	-713	-664	-649	-634	-645	-651	-655	-659	-676	-666	-639	-624	-627	-624	-623	-600
Additional Paid-In Capital	2.1%	1,264	1,238	1,219	1,192	1,171	1,140	1,118	1,090	1,068	1,035	997	968	1,025	1,003	934	847	820	794	770	744	731
Accumulated Depreciation	-	53.00	-	-	-	56.00	-	-	-	49.00	-	-	-	39.00	-	-	-	30.00	-	-	-	26.00
Shares Outstanding	0.6%	66.00	65.00	65.00	65.00	65.00	64.00	64.00	64.00	63.00	63.00	63.00	62.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	1,600	-	-	-	3,800	-	-	-	-	-	-	-	5,400	-	-	-	3,600	-	-

Cashflow (Last 12 Months)

(In Thousands)

Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	-13220.0%	-7,216	55.00	-6,323	-18,326	5,820	23,943	6,901	13,800	19,635	34,144	28,895	28,685	15,237	14,564	15,499	-20,631	19,443	23,019	3,568	-4,124	14,133
Share Based Compensation	9.6%	22,741	20,741	23,400	21,194	24,441	22,236	20,131	18,110	17,099	15,729	14,977	12,947	13,308	12,837	16,421	15,865	18,685	17,230	12,322	9,834	10,309
Cashflow From Investing	65.8%	-16,584	-48,525	5,698	-26,329	35,777	-14,163	6,357	5,197	-76,818	-39,203	-64,761	-6,094	-59,626	-137,825	-131,521	32,916	-20,901	-22,171	-14,661	778	-6,591
Cashflow From Financing	236.9%	2,617	-1,911	3,948	-541	6,100	-774	8,051	3,500	15,886	18,850	13,623	3,573	9,204	29,931	263,822	11,481	6,418	7,034	8,793	1,962	1,957

TNDM Income Statement

2023-12-31

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Income Statement [Abstract]
Sales	$ 747,718	$ 801,217	$ 702,799
Cost of sales	380,028	388,231	326,584
Gross profit	367,690	412,986	376,215
Operating expenses:
Selling, general and administrative	352,503	335,681	261,508
Research and development	169,667	139,114	92,054
Acquired in-process research and development expenses	78,750	31,039	0
Total operating expenses	600,920	505,834	353,562
Operating income (loss)	(233,230)	(92,848)	22,653
Other income (expense), net:
Interest income and other, net	22,858	6,057	674
Interest expense	(9,882)	(6,208)	(6,040)
Less: change in fair value of common stock warrants	0	147	(1,386)
Total other income (expense), net	12,976	(4)	(6,752)
Income (loss) before income taxes	(220,254)	(92,852)	15,901
Income tax expense	2,357	1,742	335
Net income (loss)	(222,611)	(94,594)	15,566
Other comprehensive income (loss):
Unrealized gain (loss) on short-term investments	3,606	(2,233)	(693)
Foreign currency translation gains (losses)	(420)	1,032	(143)
Comprehensive income (loss)	$ (219,425)	$ (95,795)	$ 14,730
Net income (loss) per share - basic (in dollars per share)	$ (3.43)	$ (1.47)	$ 0.25
Net income (loss) per share - diluted (in dollars per share)	$ (3.43)	$ (1.47)	$ 0.24
Weighted average shares used to compute basic net income (loss) per share (in shares)	64,969,000	64,146,000	63,000,000
Weighted average shares used to compute diluted net income (loss) per share (in shares)	64,969,000	64,146,000	64,349,000

TNDM Balance Sheet

2023-12-31

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 58,868	$ 172,517
Short-term investments	409,044	444,384
Accounts receivable, net	105,555	114,717
Inventories	157,937	111,117
Prepaid and other current assets	16,585	7,241
Total current assets	747,989	849,976
Property and equipment, net	76,542	68,552
Operating lease right-of-use assets	87,791	110,626
Other long-term assets	40,336	23,631
Total assets	952,658	1,052,785
Current liabilities:
Accounts payable	49,586	55,730
Accrued expenses	12,726	9,595
Employee-related liabilities	43,430	38,682
Operating lease liabilities	17,060	13,121
Deferred revenue	43,994	18,837
Other current liabilities	28,462	29,325
Total current liabilities	195,258	165,290
Convertible senior notes, net - long-term	285,035	283,232
Operating lease liabilities - long-term	113,572	123,524
Deferred revenue - long-term	13,331	16,874
Other long-term liabilities	31,830	23,918
Total liabilities	639,026	612,838
Commitments and contingencies (Note 13)	0	0
Stockholders’ equity:
Common stock, $0.001 par value; 200,000 shares authorized, 65,552 and 64,513 shares issued and outstanding at December 31, 2023 and 2022, respectively.	66	65
Additional paid-in capital	1,263,997	1,170,888
Accumulated other comprehensive income (loss)	1,369	(1,817)
Accumulated deficit	(951,800)	(729,189)
Total stockholders’ equity	313,632	439,947
Total liabilities and stockholders’ equity	$ 952,658	$ 1,052,785

About Tandem Diabetes Care Inc

Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set. It also provides t:slim X2 insulin with Basal-IQ and control IQ technology; t:slim X2 with G5 Integration; and Tandem Device Updater, a tool that allows users to update their pump's software. In addition, the company offers t:connect, a web-based data management application, which provides a visual way to display diabetes therapy management data from the pump, continuous glucose monitoring, and supported blood glucose meters for users, their caregivers, and their healthcare providers; and Sugarmate, a mobile app for people with diabetes who use insulin. It has development and commercialization agreements with Dexcom, Inc. and Abbott Laboratories. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.

CEO	Mr. John F. Sheridan
WEBSITE	tandemdiabetes.com
INDUSTRY	Medical Instruments & Supplies
EMPLOYEES	2600

Tandem Diabetes Care Inc Frequently Asked Questions

What is the ticker symbol for Tandem Diabetes Care Inc? What does TNDM stand for in stocks?

TNDM is the stock ticker symbol of Tandem Diabetes Care Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Tandem Diabetes Care Inc (TNDM)?

As of Tue Apr 16 2024, market cap of Tandem Diabetes Care Inc is 2.17 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of TNDM stock?

You can check TNDM's fair value in chart for subscribers.

What is the fair value of TNDM stock?

You can check TNDM's fair value in chart for subscribers. The fair value of Tandem Diabetes Care Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Tandem Diabetes Care Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for TNDM so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Tandem Diabetes Care Inc a good stock to buy?

The fair value guage provides a quick view whether TNDM is over valued or under valued. Whether Tandem Diabetes Care Inc is cheap or expensive depends on the assumptions which impact Tandem Diabetes Care Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for TNDM.

What is Tandem Diabetes Care Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Apr 16 2024, TNDM's PE ratio (Price to Earnings) is -9.73 and Price to Sales (PS) ratio is 2.9. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. TNDM PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Tandem Diabetes Care Inc's stock?

In the past 10 years, Tandem Diabetes Care Inc has provided -0.149 (multiply by 100 for percentage) rate of return.